10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2012 | |||
Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 27, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Cash Provided by (Used in) Operating Activities [Abstract] | |||
| Net Income | $ 2,573,599 | 2,789,059 | 2,889,749 |
| Adjustments to Reconcile Net Income to Cash Provided by Operating Activities [Abstract] | |||
| Depreciation Expense | 82,847 | 72,187 | 67,240 |
| Amortization Expense | 195,359 | 230,045 | 198,237 |
| Stock-Based Compensation Expense | 208,725 | 192,378 | 200,041 |
| In-Process Research and Development Impairment Expense | 0 | 26,630 | 136,000 |
| Excess Tax Benefits from Stock-Based Compensation | (114,236) | (40,848) | (81,620) |
| Tax Benefits from Employee Stock Plans | 112,629 | 37,231 | 82,086 |
| Deferred Income Taxes | (39,393) | 64,061 | 12,152 |
| Other | (1,878) | 47,931 | 10,408 |
| Increase (Decrease) in Operating Capital [Abstract] | |||
| Accounts Receivable, net | 197,986 | (375,736) | (348,875) |
| Inventories | (349,924) | (200,793) | (161,190) |
| Prepaid Expense and Other Assets | (129,318) | (13,959) | (70,466) |
| Accounts Payable | 117,485 | 428,944 | (4,453) |
| Income Taxes Payable | (68,473) | 110,771 | (185,733) |
| Accrued Liabilities | 386,063 | 300,593 | 120,065 |
| Deferred Revenue | 23,245 | (29,484) | (29,728) |
| Net Cash Provided by Operating Activities | 3,194,716 | 3,639,010 | 2,833,913 |
| Net Cash Provided by (Used in) Investing Activities [Abstract] | |||
| Purchases of Marketable Securities | (1,244,898) | (5,127,790) | (5,502,687) |
| Proceeds from Sales of Marketable Securities | 527,712 | 8,649,752 | 3,033,893 |
| Proceeds from Maturities of Marketable Securities | 44,813 | 788,395 | 683,927 |
| Purchases of Other Investments | (25,000) | 0 | 0 |
| Acquisitions, Net of Cash Acquired | (10,751,635) | (588,608) | (91,000) |
| Capital Expenditures | (397,046) | (131,904) | (61,884) |
| Net Cash Provided by (Used in) Investing Activities | (11,846,054) | 3,589,845 | (1,937,751) |
| Net Cash Provided by (Used in) Financing Activities [Abstract] | |||
| Proceeds from debt financing, net of issuance costs | 2,144,733 | 4,660,702 | 2,962,500 |
| Proceeds from convertible note hedges | 213,856 | 36,148 | 0 |
| Proceeds from Sale of Warrants | 0 | 0 | 155,425 |
| Proceeds from Issuances of Common Stock | 466,283 | 211,737 | 221,223 |
| Purchases of convertible note hedges | 0 | 0 | (362,622) |
| Repurchases of Common Stock | (667,041) | (2,383,132) | (4,022,593) |
| Repayments of Debt Financing | (1,837,139) | (686,135) | (500,000) |
| Repayments of Other Long-Term Obligations | (2,186) | (1,562) | (5,786) |
| Excess Tax Benefits from Stock-Based Compensation | 114,236 | 40,848 | 81,620 |
| Contributions From (Distributions to) Noncontrolling Interest | 130,604 | (115,037) | 131,523 |
| Net Cash Provided by (Used in) Financing Activities | 563,346 | 1,763,569 | (1,338,710) |
| Effect of Exchange Rate Changes on Cash | 7,909 | (16,526) | 77,469 |
| Net Change in Cash and Cash Equivalents | (8,080,083) | 8,975,898 | (365,079) |
| Cash and Cash Equivalents at beginning of period | 9,883,777 | 907,879 | |
| Cash and Cash Equivalents at end of period | 1,803,694 | 9,883,777 | 907,879 |
| Supplemental Cash Flow Information [Abstract] | |||
| Interest paid, net of amounts capitalized | 249,358 | 62,180 | 15,748 |
| Income Taxes Paid | 1,101,241 | 621,025 | 1,129,577 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |